Tenpoint Therapeutics Wins FDA Approval for Yuvezzi, Backed by $235M in New Capital

Tenpoint Therapeutics has received FDA approval for Yuvezzi, the first combination eye drop for presbyopia, with a commercial launch planned for Q2. The therapy was originally developed by Seattle-based Visus Therapeutics prior to its merger with Tenpoint. The approval coincides with $235M in new capital, combining an $85M Series B raise and a $150M debt facility to support commercialization and growth.